The PEAK data and Priority Review are strong catalysts; the stock may re-rate upward as the market prices in a high-probability approval and commercial launch in 2H 2026. Traders should watch for the PDUFA date (Nov 30, 2026) and any updates on the first-line exon 9 cohort.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $34.81entry
- T+1 · 6mo ago −5.89%α −6.03% · $32.76
- T+5 · 5mo ago −10.89%α −8.14% · $31.02
- T+20 · 5mo ago +11.18%α +12.47% · $38.70
- T+60 · 3mo ago +5.72%α +4.49% · $36.80
Price Chart
How similar events traded
Executive Summary
Cogent Biosciences reported highly positive Phase 3 PEAK trial results for bezuclastinib in combination with sunitinib in second-line GIST, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (median PFS 16.5 months vs 9.2 months, HR=0.50, p<0.0001) and objective response rate (46% vs 26%) compared to sunitinib alone. The FDA has granted Priority Review for the NDA with a PDUFA date of November 30, 2026, and the company plans to launch later this year. This is a transformative event for the company, as bezuclastinib is its lead asset and the data position it as a potential new standard of care in a large market.
Key Facts
- Bezuclastinib combination reduced risk of disease progression or death by 50% vs sunitinib alone (HR=0.50, 95% CI: 0.39-0.65, p<0.0001)
- Median PFS: 16.5 months for combination vs 9.2 months for sunitinib monotherapy
- Objective response rate: 46% for combination vs 26% for sunitinib
- FDA granted Priority Review for NDA; PDUFA date November 30, 2026
- Mean duration of treatment on combination arm estimated at 21.4 months
- PFS2 (time to progression on next therapy or death) median not reached vs 21 months (HR=0.57)
- Safety profile generally consistent with sunitinib alone; no unique combination risks observed
- Initiated new clinical trial of bezuclastinib combination in first-line GIST patients with KIT exon 9 mutations
Financial Impact
Transformative for a $6.0B market cap company with a single lead asset; potential peak sales in GIST could exceed $1B annually given standard-of-care positioning in second-line and expansion into first-line
Risk Factors
- PDUFA delay or complete response letter (CRL) from FDA, especially on CMC or safety grounds
- Competition from other KIT inhibitors (e.g., ripretinib, avapritinib) in GIST
- Commercial execution risk for a first launch by a small biotech
- Potential transient ALT/AST elevations requiring monitoring and dose management
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303872 |
Track record
13 reports on COGT
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- May 30, 202624w ago Press Release Bullish 8/10 Viewing Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
- May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers